Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 9:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 1,622 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Retinal Disorder Clear all

Conditions: Neovascular Age-Related Macular Degeneration (nAMD)
Interventions: AXT107 0.1 mg, AXT107 0.25 mg, AXT107 0.5 mg; Drug
Lead sponsor: AsclepiX Therapeutics, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 10
States / cities: Gilbert, Arizona • Los Angeles, California • St. Petersburg, Florida + 7 more

Conditions: Exudative Macular Degeneration
Interventions: TRIPLE COMBINATION THERAPY; Procedure
Lead sponsor: The Retina Center of St. Louis County, PC; Other
Eligibility: 50 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Adrenocortical Carcinoma, Gastrointestinal Carcinoid Tumor, Kidney Cancer, Neuroblastoma, Retinoblastoma, Sarcoma
Interventions: Seneca Valley virus-001, cyclophosphamide, laboratory biomarker analysis, pharmacological study; Biological · Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Years to 21 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 18
States / cities: Birmingham, Alabama • Orange, California • San Francisco, California + 15 more

Conditions: Ehlers-Danlos Syndrome, Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Genetic Disease Investigators; Other
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Colleyville, Texas

Conditions: Retinal Vein Occlusion, Macular Edema, Cystoid, Macular Edema
Interventions: Triamcinolone Acetonide; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 1,260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Mitochondrial Disorders, Mitochondrial Genetic Disorders, Mitochondrial Diseases, Disorder of Mitochondrial Respiratory Chain Complexes, Deletion and Duplication of Mitochondrial DNA
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2026
U.S. locations: 16
States / cities: San Diego, California • Stanford, California • Aurora, Colorado + 12 more

Conditions: Age Related Macular Degeneration (AMD)
Interventions: SPIN, Non-aerobic, stretching/balance intervention Control; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 65 Years to 89 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Diabetic Retinopathy
Interventions: Nepafenac ophthalmic suspension, 0.1% (NEVANAC®), Nepafenac ophthalmic suspension vehicle; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Primary Open Angle Glaucoma
Interventions: AMDX-2011P; Drug
Lead sponsor: Amydis Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Phoenix, Arizona • Glendale, California • Newport Beach, California

Conditions: Retinal Hemangioblastoma, Von Hippel-Lindau Disease
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 7 Years to 120 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Macular Hole, RPE Detachment, Epiretinal Membrane, Posterior Vitreous Detachment
Interventions: Not listed
Lead sponsor: The New York Eye & Ear Infirmary; Other
Eligibility: 18 Years to 95 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: New York, New York

Conditions: Non-Proliferative Diabetic Retinopathy
Interventions: Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24, Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24, Sham/mock procedure of intravitreal injection followed by a second sham/mock procedure at Week 24; Drug · Other
Lead sponsor: Ocular Therapeutix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 930 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Hagerstown, Maryland

Conditions: Age-Related Macular Degeneration
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 50 Years to 90 Years
Enrollment: 238 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Retinal Vein Occlusion
Interventions: Aflibercept Ophthalmic; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Uveitis, Macular Edema
Interventions: Efalizumab; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: X-Linked Retinitis Pigmentosa (XLRP)
Interventions: Adeno-associated virus vector expressing a human RPGR gene; Biological
Lead sponsor: Beacon Therapeutics; Industry
Eligibility: 12 Years to 50 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 6
States / cities: Jacksonville, Florida • Miami, Florida • Durham, North Carolina + 3 more

Conditions: Macular Degeneration
Interventions: MSI-1256F (Squalamine Lactate); Drug
Lead sponsor: Genaera Corporation; Industry
Eligibility: 50 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 9
States / cities: Boynton Beach, Florida • Fort Meyers, Florida • Miami, Florida + 6 more

Conditions: Glaucoma
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 260 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Leukemia, Lymphoma, Metastatic Cancer, Retinoblastoma, Sarcoma
Interventions: busulfan; Drug
Lead sponsor: Pediatric Brain Tumor Consortium; Network
Eligibility: 3 Years to 21 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 8
States / cities: San Francisco, California • Washington D.C., District of Columbia • Boston, Massachusetts + 5 more

Conditions: Central Retinal Vein Occlusion, Choroidal Neovascularization, Age-related Macular Degeneration, Branch Retinal Vein Occlusion
Interventions: Conj flora Antibiotic resistance; Procedure
Lead sponsor: Mid Atlantic Retina; Other
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Retinal Diseases
Interventions: Not listed
Lead sponsor: Retina Institute of Hawaii; Other
Eligibility: 50 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Central Retinal Vein Occlusion
Interventions: Ranibizumab; Drug
Lead sponsor: California Retina Consultants; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 4
States / cities: Bakersfield, California • Oxnard, California • Santa Barbara, California + 1 more

Conditions: Diabetic Retinopathy
Interventions: OTT166, Vehicle control; Drug
Lead sponsor: OcuTerra Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 67
States / cities: Peoria, Arizona • Phoenix, Arizona • Beverly Hills, California + 59 more

Conditions: Diabetes Mellitus
Interventions: Diabetes Mobile Application; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 14 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration

Triple Combination Therapy of Choroidal Neovascularization in AMD, a Cost Effect and Efficient Therapeutic Treatment

Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features

Vascular Fundus Changes in Patients With High Probability of Chronic Cerebrospinal Venous Insufficiency (CCSVI)

Steroid Injections vs. Standard Treatment for Macular Edema Due to Retinal Blood Vessel Blockage

North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)

Active AMD Study to Improve Function in Veterans

Macular Edema Incidence/Severity Reduction With Nevanac

A Study of AMDX-2011P in Participants With Primary Open Angle Glaucoma

Retrospective Case Series of Trans-scleral Cryotherapy for Retinal Hemangioblastoma

Comparison of a Spectral OCT/SLO With the Stratus OCT for Imaging Various Retinal Pathologies

A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy

Brain Connectivity in Age-Related Macular Degeneration

Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment

Efalizumab to Treat Uveitis

A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa

A Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration

Macular Damage in Early Glaucoma and Progression

Busulfan in Treating Children and Adolescents With Refractory CNS Cancer

A Research Study to Evaluate the Effects of Repeated Intravitreal Injections on Bacteria Around the Eye

Measuring Corneal Cells With Specular Microscopy

Lucentis for Central Retinal Vein Occlusion (CRVO)

Nesvategrast (OTT166) in Diabetic Retinopathy (DR)

Mobile Application to Enhance Diabetic Care